AEMD:NSD-Aethlon Medical Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 3.43

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.35M

Avg Analyst Target

USD 8.33 (+142.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California. Address: 9635 Granite Ridge Drive, San Diego, CA, United States, 92123

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

N/A

USD46.73B 67.32 46.35
PODD Insulet Corporation

N/A

USD20.96B 2,208.27 254.01
ABMD Abiomed Inc

N/A

USD15.98B 104.13 53.69
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

N/A

USD11.83B 50.48 26.26
TNDM Tandem Diabetes Care Inc

N/A

USD8.02B 1,234.76 240.61
SWAV ShockWave Medical Inc

N/A

USD7.47B N/A N/A
INMD InMode Ltd

N/A

USD6.45B 56.51 48.35
IART Integra LifeSciences Holdings ..

N/A

USD5.99B 29.34 18.71
LIVN LivaNova PLC

N/A

USD4.31B 77.40 N/A

ETFs Containing AEMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.87% 69% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.87% 69% D+ 79% C+
Trailing 12 Months  
Capital Gain 107.88% 82% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.88% 82% B- 88% B+
Trailing 5 Years  
Capital Gain -26.39% 38% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.39% 38% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 59.25% 74% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.25% 74% C 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 164.51% 18% F 9% F
Risk Adjusted Return 36.02% 51% F 51% F
Market Capitalization 0.05B 17% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.96 73% C 90% A-
Price/Book Ratio 2.12 81% B- 58% F
Price / Cash Flow Ratio -7.80 53% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.98% 41% F 31% F
Return on Invested Capital -84.97% 15% F 9% F
Return on Assets -25.35% 25% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.11 96% A 96% A
Short Percent 3.31% 59% F 46% F
Beta 0.57 79% C+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector